Industry
Biotechnology
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Loading...
Open
0.54
Mkt cap
6.6M
Volume
86K
High
0.55
P/E Ratio
-0.32
52-wk high
2.45
Low
0.53
Div yield
N/A
52-wk low
0.41
Portfolio Pulse from Benzinga Insights
October 29, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 12:51 pm
Portfolio Pulse from Benzinga Insights
October 16, 2024 | 12:10 pm
Portfolio Pulse from Benzinga Insights
October 15, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 8:15 pm
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 11:08 am
Portfolio Pulse from Benzinga Newsdesk
May 24, 2024 | 12:17 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 1:41 pm
Portfolio Pulse from Avi Kapoor
April 24, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Insights
April 23, 2024 | 8:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.